Repligen shells out $150M for New Hampshire biotech

Waltham drug developer Repligen is paying $150 million in cash and stock to acquire a New Hampshire-based chromatography developer called Avitide Inc.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.